par Brennand, Kristen Jennifer;McConnell, Michael M.J.;McKay, Ronald D G R.D.;Morrow, Eric E.M.;Muotri, Alysson Renato;Panchision, David D.M.;Rubin, Lee L.L.;Sawa, Akira;Soldner, Frank;Song, Hongjun;Studer, Lorenz;Marchetto, Maria Carol Arolina M.C.;Temple, Sally;Vaccarino, Flora F.M.;Wu, Junxi;Vanderhaeghen, Pierre ;Gage, Fred H F.H.;Jaenisch, Rudolf;Benvenisty, Nissim;Brüstle, Oliver;Ebert, Allison;Izpisua Belmonte, Juan Carlos;Kaykas, Ajamete;Lancaster, Madeline M.A.;Livesey, Frederick F.J.
Référence Stem Cell Reports, 5, 6, page (933-945)
Publication Publié, 2015-12
Référence Stem Cell Reports, 5, 6, page (933-945)
Publication Publié, 2015-12
Article révisé par les pairs
Résumé : | As a group, we met to discuss the current challenges for creating meaningful patient-specific in vitro models to study brain disorders. Although the convergence of findings between laboratories and patient cohorts provided us confidence and optimism that hiPSC-based platforms will inform future drug discovery efforts, a number of critical technical challenges remain. This opinion piece outlines our collective views on the current state of hiPSC-based disease modeling and discusses what we see to be the critical objectives that must be addressed collectively as a field. |